A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

Publisher: John Wiley & Sons Inc

E-ISSN: 1523-4681|30|2|216-224

ISSN: 0884-0431

Source: JOURNAL OF BONE AND MINERAL RESEARCH, Vol.30, Iss.2, 2015-02, pp. : 216-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content